Green Elephant Biotech Highlights 74% Cost Reduction Potential and Accelerated Development in Cell & Gene Therapy Through Automation

July 19, 2026

Green Elephant Biotech Germany

Overview

Green Elephant Biotech has highlighted the potential of automation platforms to significantly reduce development timelines and manufacturing costs in cell and gene therapy (CGT). Cases like Multiply Labs demonstrate up to a 74% cost reduction through automation, alongside accelerated development. The company emphasizes that optimizing viral vector manufacturing and streamlining regulatory pathways are crucial for rapid CGT commercialization.

In Depth

Key Findings

Green Elephant Biotech has presented a compelling case for automation platforms as a transformative solution to the protracted development timelines and high costs currently prevalent in cell and gene therapy (CGT). According to their analysis, automated manufacturing platforms, exemplified by Multiply Labs, have the potential to achieve up to a 74% reduction in CGT manufacturing costs and substantially shorten overall development cycles. This finding underscores the critical importance of optimizing viral vector manufacturing and streamlining regulatory pathways for the swift commercialization of CGT products.

Technical and Clinical Details

Automation in CGT manufacturing minimizes manual intervention, thereby improving process consistency and reproducibility and significantly reducing the risk of human error. This allows for the minimization of quality variability between manufacturing batches and maximizes product yield. Viral vectors, such as lentiviral and adeno-associated viral (AAV) vectors, are indispensable for gene therapy delivery, but their production is complex and costly. Automated, closed systems streamline the production of these vectors, facilitating easier scale-up. Furthermore, automation enhances aseptic processing and mitigates contamination risks, ultimately bolstering the safety profile of the final cell and gene therapy products.

Background and Industry Context

Currently, the development process for CGT products typically spans an average of eight years, coupled with exceedingly high manufacturing costs. These challenges stem from the inherent characteristics of personalized therapies (autologous cell therapies), intricate manufacturing protocols, stringent quality control requirements, and a scarcity of skilled personnel. Such factors collectively impede the widespread adoption and patient access to groundbreaking CGT products. The industry is actively responding by investing heavily in process standardization, digitalization, and automation technologies to accelerate development and reduce costs. Regulatory bodies are also promoting the adoption of Advanced Manufacturing Technologies (AMTs), signaling a strong demand for innovative manufacturing solutions.

Strategic Significance and Outlook

Automation technology holds immense potential to revolutionize the CGT industry by resolving critical manufacturing bottlenecks and enabling more efficient and cost-effective production. It is anticipated that a growing number of companies will adopt automated platforms, leading to further advancements in digital twins for manufacturing processes and AI-driven optimization. This will accelerate the market entry of CGT products, expanding therapeutic options for a broader range of diseases. Moreover, reduced manufacturing costs will play a decisive role in lowering the price of high-cost therapies like CAR-T cell therapy, thereby increasing patient access. Green Elephant Biotech aims to support these technological innovations and contribute to the sustainable growth of the CGT industry.

Source: https://greenelephantbiotech.com/blog/cell-therapy-development/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.